ImmunityBio reported encouraging early results from its off‑the‑shelf CD19 CAR‑NK program in a small Phase 1 cohort for Waldenström’s lymphoma, with complete responses sustained up to 15 months in some patients. Four patients enrolled in the QUILT‑106 study received multiple outpatient doses of the allogeneic CAR‑NK product in combination with rituximab and achieved durable disease control without lymphodepleting chemotherapy, the company said. The dataset is small and early, but the durability and outpatient dosing profile cited by ImmunityBio have immediate operational and commercial implications if reproduced in larger cohorts. Off‑the‑shelf NK therapies aim to reduce manufacturing time and broaden access compared with autologous cell products; confirming durability and safety without lymphodepletion is critical to that value proposition.